ReviewBiosensors2025
Recent Advances in Antibody Discovery Using Ultrahigh-Throughput Droplet Microfluidics: Challenges and Future Perspectives.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Decoding Cellular Heterogeneity with Microfluidic Single-Cell Secretion Analysis Tools.ACS omega · 2026Review
- From Single Cells to Silicon: Emerging Technologies Transforming Monoclonal Antibody Discovery.Antibodies (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Droplet microfluidics has emerged as a transformative technology that can substantially increase the throughput of antibody "hit" discovery. This review provides a comprehensive overview of the recent advances in this dynamic field, focusing primarily on the technological and methodological innovations that have enhanced the antibody discovery process. This investigation starts with the fundamental principles of droplet microfluidics, emphasizing its unique capabilities for precisely controlling and manipulating picoliter-volume droplets. This discussion extends to various assay types employed in droplet microfluidics, including binding assays, functional assays, Förster Resonance Energy Transfer (FRET) assays, internalization assays, and neutralization assays, each offering distinct advantages for antibody screening and characterization. A critical examination of methods to improve droplet encapsulation is presented, besides addressing challenges such as reducing the leakage of small molecules from droplets and explaining what a "hit" droplet looks like. Furthermore, we assess design considerations essential for implementing high-throughput fluorescence-activated droplet sorting (FADS) workstations and emphasize the need for automation. This review also delves into the evolving commercial landscape, identifying key market players and emerging industry trends. This review paper aims to catalyze further research and innovation, ultimately advancing the field towards more efficient and robust solutions for antibody identification and development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.